文献速递类风湿关节炎

类风湿关节炎患者中小剂量糖皮质激素处方与心血管结局的关联

Association of Cardiovascular Outcomes With Low-Dose Glucocorticoid Prescription in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2024-07-23

基于两个理赔数据库的队列研究,纳入病情稳定使用改善病情抗风湿药超过180天的类风湿关节炎患者,评估糖皮质激素剂量与复合心血管结局(卒中或心肌梗死)的关联。在年龄较大、合并症较多的美国联邦医疗保险(Medicare)队列中,糖皮质激素与复合心血管结局呈剂量依赖性增加相关,即使剂量≤5 mg/日;在较年轻、心血管风险较高的亚组中亦见剂量依赖性增加,而在较年轻、较健康的Optum去标识化Clinformatics Data Mart(CDM)队列中未见显著关联。

要点

  • 在年龄较大、合并症较多的Medicare队列中,糖皮质激素与复合心血管结局呈剂量依赖性增加相关,即使剂量≤5 mg/日。
  • 在较年轻、心血管风险较高的类风湿关节炎亚组中,糖皮质激素亦与复合心血管结局呈剂量依赖性增加相关。
  • 在较年轻、较健康的CDM队列中,糖皮质激素与复合心血管结局无显著关联。

核心结论

  • 在病情稳定使用改善病情抗风湿药的年龄较大、合并症较多的类风湿关节炎患者及较年轻、心血管风险较高的患者中,糖皮质激素与心肌梗死和卒中的剂量依赖性风险增加相关,即使剂量≤5 mg/日。
  • 在较年轻、较健康的类风湿关节炎患者中,未观察到糖皮质激素与复合心血管结局的关联。

研究设计与样本

  • 使用两个理赔数据库识别病情稳定使用改善病情抗风湿药超过180天的类风湿关节炎患者。
  • 采用逆概率加权和聚类以处理多次观察的比例风险模型,估计糖皮质激素剂量对复合心血管结局(卒中或心肌梗死)的影响。
  • Medicare队列135,583例患者,Optum去标识化Clinformatics Data Mart(CDM)数据库队列39,272例患者。

主要发现

  • Medicare和CDM队列的复合心血管结局发生率分别为每100人年1.3和0.8。
  • 在年龄较大、合并症较多的Medicare队列中,调整模型显示糖皮质激素与复合心血管结局呈剂量依赖性增加相关,预测一年发生率:≤5 mg组1.4%(95%CI 1.2%-1.6%),>5至10 mg组1.6%(95%CI 1.4%-1.9%),>10 mg组1.8%(95%CI 1.2%-2.5%),未使用糖皮质激素组1.1%(95%CI 1.1%-1.2%)。
  • 在CDM队列中,糖皮质激素与复合心血管结局无显著关联。
  • 在较年轻、心血管风险较高的类风湿关节炎患者亚组中,糖皮质激素与复合心血管结局呈剂量依赖性增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Many guidelines recommend limiting glucocorticoids in patients with rheumatoid arthritis (RA), but 40% of patients remain on glucocorticoids long term. We evaluated the cardiovascular risk of long-term glucocorticoid prescription by studying patients on stable disease-modifying antirheumatic drugs (DMARDs). METHODS: Using two claims databases, we identified patients with RA on stable DMARD therapy for >180 days. Proportional hazards models with inverse-probability weights and clustering to account for multiple observations were used to estimate the effect of glucocorticoid dose on composite cardiovascular outcomes (stroke or myocardial infarction [MI]). RESULTS: There were 135,583 patients in Medicare and 39,272 in Optum's de-identified Clinformatics Data Mart (CDM) database. Medicare and CDM patients had an incidence of 1.3 and 0.8 composite cardiovascular outcomes per 100 person-years, respectively. In the older, comorbid Medicare cohort, glucocorticoids were associated with a dose-dependent increase in composite cardiovascular outcomes in adjusted models with predicted one-year incidence of 1.4% (95% confidence interval [CI] 1.2%-1.6%) for ≤5 mg, 1.6% (95% CI 1.4%-1.9%) for >5 to 10 mg, and 1.8% (95% CI 1.2%-2.5%) for >10 mg versus 1.1% (95% CI 1.1%-1.2%) among patients not receiving glucocorticoids. There was no significant association among the CDM cohort. However, in the subgroup of younger patients with RA and higher cardiovascular risk, glucocorticoids were associated with a dose-dependent increase in composite cardiovascular outcomes. CONCLUSION: Among older patients with more comorbidities and younger patients with higher cardiovascular risk with RA on stable DMARD therapy, glucocorticoids were associated with a dose-dependent increased risk of MI and stroke, even at doses ≤5 mg/day. By contrast, no association was noted among younger, healthier patients with RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Coburn BW, Baker JF, Hsu JY, et al. Association of Cardiovascular Outcomes With Low-Dose Glucocorticoid Prescription in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2024. PMID: 38923870. doi:10.1002/art.42928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。